Colorectal Cancer (CRC) Active Not Recruiting Phase 2 Trials for Nivolumab (DB09035)

Back to Colorectal Cancer (CRC)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

Indication	Status	Phase
DBCOND0031867 (Colorectal Cancer (CRC))	Active Not Recruiting	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT04729322	Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders	Treatment	Fecal microbiota (DB17743) Metronidazole (DB00916) Neomycin (DB00994) Nivolumab (DB09035) Pembrolizumab (DB09037) Vancomycin (DB00512)
NCT03104439	Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer	Treatment	Ipilimumab (DB06186) Nivolumab (DB09035)
NCT04730544	Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.	Treatment	Ipilimumab (DB06186) Nivolumab (DB09035)
NCT04963283	Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer	Treatment	Cabozantinib (DB08875) Nivolumab (DB09035)
NCT03228667	QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors	Treatment	Atezolizumab (DB11595) Avelumab (DB11945) Docetaxel (DB01248) Durvalumab (DB11714) Inbakicept (DB16479) Nivolumab (DB09035) Nogapendekin alfa (DB18740) PD-L1 t-haNK (DB23689) Pembrolizumab (DB09037)
NCT07523763	Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer	Treatment	Nivolumab (DB09035) Pembrolizumab (DB09037)